Task: Disability

The 2023 Canadian Clinical Guidelines for Alcohol Use Disorder quietly—but dramatically—redefine what constitutes “appropriate treatment.” In doing so, they disrupt long-standing clinical assumptions and introduce serious downstream consequences for disability adjudication, insurance decision-making, and claims management. 

Most notably, the guidelines advise against prescribing antidepressants to individuals with active alcohol use disorder, directly contradicting treatment pathways still embedded in many adjudication frameworks. At the same time, they promote anti-craving medications such as naltrexone as first-line therapy—despite the reality that only a small fraction of Canadian patients with active AUD ever receive these prescriptions.

This disconnect creates a high-stakes adjudication gap: claimants may be labeled “non-compliant” for not receiving medications that are rarely prescribed in real-world practice, while clinicians are simultaneously discouraged from using treatments insurers may still expect to see. Managers and adjudicators are now forced to reconcile strict, updated medical standards with the uneven realities of frontline care. 

This session explores how these guidelines challenge traditional definitions of compliance, appropriate treatment, and recovery—and what insurers, case managers, and medical consultants must do to adapt.